Activity of Daptomycin, Linezolid, Vancomycin and Combinations against Methicillin- Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model

  • Presented at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in 2013
  • 1,2 and Kerry L. LaPlante 1,2,3

Research

BACKGROUND: Vancomycin is the standard treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections, however nonsusceptibility and treatment failure underscore the need for more treatment options. Current MRSA treatment guidelines recommend daptomycin in combination with linezolid as an option in cases of persistent bacteremia or vancomycin treatment failure. No clinical data has been published on the activity using these combinations. We investigated the activity of daptomycin, linezolid, and vancomycin alone and in combination against MRSA in an in vitro pharmacodynamic model simulating bacteremia over 48 hours.
Related People: Kerry L. LaPlante
1Veterans Affairs Medical Center, Providence, RI;
2 University of Rhode Island, College of Pharmacy, Kingston, RI;
3 Warren Alpert Medical School of Brown University, Providence, RI